CT-3001
/ Crossignal Therap
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
September 25, 2024
A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=78 | Recruiting | Sponsor: Crossignal Therapeutics, Inc. | Not yet recruiting ➔ Recruiting
Enrollment open • Metastases • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • IFNG • TGFB1 • TNFA
September 21, 2024
A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=78 | Not yet recruiting | Sponsor: Crossignal Therapeutics, Inc.
Metastases • New P1/2 trial • Colorectal Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • IFNG • TGFB1 • TNFA
1 to 2
Of
2
Go to page
1